Navigation Links
Loxapine in Medical News

Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002

...art of that transaction, Alexza licensed to Symphony Allegro its Staccato loxapine program and its Staccato alprazolam program. Since that time, Alexza has...ed certain intellectual property rights to Staccato alprazolam and Staccato loxapine in connection with our Symphony Allegro arrangement and will not receive ma...

Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008

...ide $50 million of funding through Symphony Allegro, an affiliate of Symphony Capital, for additional clinical and nonclinical development of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-002). Alexza continues to be primarily responsible for the development of these three product candidat...
Loxapine in Medical Technology

Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches

...l established Symphony Allegro, Inc., which is providing funding to Alexza to accelerate clinical and other related development activities of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-002). Alexza has granted a license to certain intellectual property rights for the selected product c...

Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

...s a potentially important new drug candidate for treating acute agitation. loxapine is a well established antipsychotic and the Staccato system enables patient...to accelerate clinical and other related development activities of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-002). Alexza has granted a...

Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients

...resident, Research and Development. "We believe that the ability to provide loxapine via our Staccato technology, thus combining a drug with a well-established ...to accelerate clinical and other related development activities of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-002). Alexza has granted a ...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

...t the patients remained in the clinic. Alexza's original IND for Staccato loxapine was filed with the Division of Neuropharmacological Drug Products of the FD...ducts, or DPP, and the Division of Neurology Products, or DNP. The Staccato loxapine IND was transferred to the DPP, as the AZ-004 development program is for a ...

Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

...ive nature and rapid pharmacokinetic (PK) properties resulting from inhaled loxapine administration via the Staccato system have the potential to make AZ-004 a ...e end of September 2008. The Company believes that the unique delivery of loxapine via the Staccato system will provide rapid onset of drug effect, as measure...

Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting

...FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it will present results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American Headache Society, which being held at the Marrio...

Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation

...er designed to generate and deliver excipient-free loxapine aerosol for deep lung delivery that results in IV-... The Company believes that the unique delivery of loxapine via the Staccato system will provide rapid onset o...d other related development activities of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-00...

Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting

...tion annual meeting the results of a Phase 2a clinical trial of Staccato(R) loxapine (AZ-004) for the treatment of acute agitation in schizophrenic patients. The poster presentation, "Inhaled loxapine Rapidly Improves Acute Agitation in Schizophrenic Patients" (Presentation N...

Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache

...ient-free drug aerosol for deep lung delivery that results in IV-like pharmacokinetics. In a Phase 1 dose-escalation clinical trial, doses of Staccato loxapine ranging from 0.625 to 10 mg were generally well tolerated and there were no serious adverse events. Across all doses, pharmacokinetic analyses reveale...

Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients

...stem with loxapine, a drug belonging to the class of compounds known as antipsychotics. In a Phase 1 dose-escalation clinical trial, doses of Staccato loxapine ranging from 0.625 to 10 mg were generally well tolerated and there were no serious adverse events. Across all doses, pharmacokinetic analyses reveale...
Loxapine in Biological Technology

Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

...ive nature and rapid pharmacokinetic (PK) properties resulting from inhaled loxapine administration via the Staccato system have the potential to make AZ-004 a ... schizophrenic patients. The Company believes that the unique delivery of loxapine via the Staccato system will provide rapid onset of drug effect, as measure...
Other Tags
(Date:5/5/2015)... Skedans Systems a division of ... Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 ... provides tooling to deliver real time information for decision ... Sensor Collaboration Platform is a single unified cloud software ... Web Real Time Communications (WebRTC), and commercial Unmanned Autonomous ...
(Date:5/5/2015)... May 05, 2015 In a April 25, ... The Herald-Times , the Missouri State Highway Patrol (MSHP) announced ... production or use for the second year in a row. ... the FBI, reported 1,469 incidents in 2014 alone, around 15% ... around 2% of the US Population calls Indiana home, according ...
(Date:5/5/2015)... 2015 MAP Health Management, LLC, a ... management for addiction treatment facilities, announced today that Jimmy ... Business Development. Mr. Mooney, who has more than 35 ... be responsible for developing new strategic partnerships with substance ... products and new initiatives. , Prior to joining MAP, ...
(Date:5/5/2015)... York, NY (PRWEB) May 05, 2015 ... Platform that enables businesses to deploy Mobile Engagement Campaigns ... Constant Contact . ProTexting clients can now leverage the ... reach by collecting and syncing subscribers’ e-mail addresses into ... says “We have recognized that the growing trend of ...
(Date:5/5/2015)... 2015 Okyanos, the leader in ... The study was conducted to determine the emotional impact ... and sports-related injuries have had on those affected. ... most prevalent symptom reported at 73%, followed by 66% ... and bending over. Over half of respondents, 56%, said ...
Breaking Medicine News(10 mins):Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2Health News:A Forever Recovery Releases New Information on the Epidemic Rise Of Methamphetamine Abuse in Midwest America 2Health News:Jimmy Mooney, an Addiction Treatment Veteran, Named Vice President of Business Development at MAP Health Management, LLC 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 3
(Date:4/27/2015)... FORT LAUDERDALE, Fla. , Apr. 27, 2015 /PRNewswire/ ... provider of access control and security systems is pleased ... joined the company as a consultant and member of ... Bedore is widely known as a thought leader ... Socrates Distance Learning Technology Group, and has published studies ...
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading ... ways to more fully engage with their communities around ... industry-leading, privacy protected and secure API.  ... enables the most accessible, affordable, and convenient vehicle to ... The API will allow ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
Other Contents